Liquid Biopsy Market to Witness Robust Growth by 2028

The liquid biopsy market was estimated at USD 2.83 billion in 2022 and is expected to grow at a CAGR of 17.99% during 2023-2028 to reach USD 7.64 billion in 2028.
What is a liquid biopsy?
A liquid biopsy is a minimally invasive medical procedure that involves analyzing a blood sample or other bodily fluids to detect and monitor various diseases, including cancer. Unlike traditional biopsies, which require invasive surgical procedures, liquid biopsies offer a non-invasive alternative that can be performed more frequently and with less risk to the patient. Liquid biopsies can detect various biomarkers, such as circulating tumour cells (CTCs), cell-free DNA (cfDNA), and exosomes, providing valuable information on the existence and progression of cancer and other diseases. Liquid biopsies have the potential to revolutionize cancer diagnosis and treatment, as they enable doctors to monitor patients more closely and make more informed decisions about their care.